Skip to main content
Fig. 4 | Critical Care

Fig. 4

From: The immunomodulating activity of trimodulin (polyvalent IgM, IgA, IgG solution): a post hoc analysis of the phase II CIGMA trial

Fig. 4

Mortality rates in sCAP patients treated with trimodulin or placebo. A Mortality in sCAP patients with IgM deficiency, combined with an impaired cellular immune status. B Mortality in sCAP patients with low IgM, neutrophilia, or lymphopenia combined with a hyperinflammatory status (PCT ≤ 10 µg/L, or CRP ≥ 70 mg/L). p-values were calculated by Chi-square tests. Subgroup criteria are presented in Table 1. 1Previously published data from the CIGMA trial [12] and included here for reference and completeness. ALC absolute lymphocyte count, ANC absolute neutrophil counts, CRP C-reactive protein, Ig immunoglobulin, NLR neutrophil-to-lymphocyte ratio, PCT procalcitonin, sCAP severe community-acquired pneumonia

Back to article page

Critical Care

ISSN: 1364-8535